Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Technical Officer | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,915 |
Ending reported balance
After 2026-08-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-13 · Exercise / conversion · Acquired 2,024 · Balance 20,994 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. Row 2 · 2026-08-13 · Sale · Disposed 5,079 · Balance 15,915 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2032-02-08 | Direct | 5,945 |
Reported balance
After 2026-08-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-13 · Exercise / conversion · Disposed 2,024 · Balance 5,945 F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. F2: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
F2: The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2025 Filed Feb 12, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 791 | $57.51 | $45,490.41 |
DisclosureSEC source: 0001104659-25-011679 · tm256299-4_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,084 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,562 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-011679 · tm256299-4_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-011679 · tm256299-4_4seq1.xml · derivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,656 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-011679 · tm256299-4_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 02:26 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,281 | $59.43 | $76,129.83 |
DisclosureSEC source: 0001104659-25-009286 · tm255457-4_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,657 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 02:26 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-009286 · tm255457-4_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,874 Underlying: Common Stock · 3,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 02:26 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-009286 · tm255457-4_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 5,312 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001104659-24-117941 · tm2428383-3_4seq1.xml · derivative · entry 7 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,312 shares Expires 2030-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 7,969 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-24-117941 · tm2428383-3_4seq1.xml · derivative · entry 6 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,922 Underlying: Common Stock · 7,969 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 700 | $67.83 | $47,484.01 |
DisclosureSEC source: 0001104659-24-117941 · tm2428383-3_4seq1.xml · nonDerivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $67.51 to $68.5099. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,977 | $67.05 | $400,781.76 |
DisclosureSEC source: 0001104659-24-117941 · tm2428383-3_4seq1.xml · nonDerivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 700 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $66.5 to $66.4999. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 6,604 | $65.73 | $434,074.98 |
DisclosureSEC source: 0001104659-24-117941 · tm2428383-3_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,677 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $65.35 to $66.3499. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,312 | $21.38 | $113,570.56 |
DisclosureSEC source: 0001104659-24-117941 · tm2428383-3_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2024 Filed Nov 14, 2024 02:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 7,969 | $6.80 | $54,189.20 |
DisclosureSEC source: 0001104659-24-117941 · tm2428383-3_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 10,468 | $0.00 Strike: $27.35 | $0.00 |
DisclosureSEC source: 0001104659-24-080910 · tm2419729-1_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,032 Underlying: Common Stock · 10,468 shares Expires 2033-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 10,468 | $53.00 | $554,816.56 |
DisclosureSEC source: 0001104659-24-080910 · tm2419729-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on May 5, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $53.00 to $53.060. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,468 | $27.35 | $286,299.80 |
DisclosureSEC source: 0001104659-24-080910 · tm2419729-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 5,313 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001104659-24-080214 · tm2419477-1_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,297 Underlying: Common Stock · 5,313 shares Expires 2030-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5,313 | $50.01 | $265,724.91 |
DisclosureSEC source: 0001104659-24-080214 · tm2419477-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on May 5, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.00 to $50.07. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,313 | $21.38 | $113,591.94 |
DisclosureSEC source: 0001104659-24-080214 · tm2419477-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:21 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 3,984 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-24-060559 · tm2414300-1_4seq1.xml · derivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,875 Underlying: Common Stock · 3,984 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:21 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 500 | $39.10 | $19,551.00 |
DisclosureSEC source: 0001104659-24-060559 · tm2414300-1_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on May 5, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.05 to $40.0499. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:21 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,484 | $38.38 | $133,707.56 |
DisclosureSEC source: 0001104659-24-060559 · tm2414300-1_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 530 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on May 5, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $37.96 to $38.9599. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 09, 2024 Filed May 13, 2024 20:21 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,984 | $6.80 | $27,091.20 |
DisclosureSEC source: 0001104659-24-060559 · tm2414300-1_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2024 Filed Mar 22, 2024 20:55 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 18,235 | $40.34 | $735,599.90 |
DisclosureSEC source: 0001104659-24-037927 · tm249484-2_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.00 to $40.89. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:56 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 15,515 | $39.22 | $608,498.30 |
DisclosureSEC source: 0001104659-24-036317 · tm249308-5_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,265 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.06 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 50,250 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-24-026155 · tm246920-2_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,250 Underlying: Common Stock · 50,250 shares Expires 2034-02-15 F4 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026155 · tm246920-2_4seq1.xml · derivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantCommon Stock | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026155 · tm246920-2_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,780 F1 · shares: The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 23:14 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,089 | $50.01 | $54,460.89 |
DisclosureSEC source: 0001104659-24-024605 · tm246165-6_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 473 | $49.84 | $23,574.32 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 9 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,984 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 23:14 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,865 | $50.00 | $93,250.00 |
DisclosureSEC source: 0001104659-24-024605 · tm246165-6_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,119 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 791 | $51.38 | $40,641.58 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 8 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,457 F3 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 1,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · derivative · entry 12 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,562 Underlying: Common Stock · 1,562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F8 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F8 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 1,562 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 7 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 69,190 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · derivative · entry 11 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,610 Underlying: Common Stock · 69,190 shares Expires 2030-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · derivative · entry 10 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,312 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 100 | $51.52 | $5,152.00 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 6 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,686 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 23,397 | $50.88 | $1,190,502.53 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 5 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,786 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $50.47 to $51.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 48,177 | $50.14 | $2,415,503.24 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,183 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $49.47 to $50.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 100 | $48.24 | $4,824.00 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,360 F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 5, 2023. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 69,190 | $21.38 | $1,479,282.20 |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:46 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022537 · tm246165-2_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2024 Filed Nov 14, 2024 02:01 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 3,985 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001104659-24-117940 · tm2428383-2_4aseq1.xml · derivative · entry 4 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,875 Underlying: Common Stock · 3,985 shares Expires 2022-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment is being filed to correct the number of options exercised in row two of each of Table I and Table II in the originally filed Form 4 on February 13, 2024; and to report the exercise of the options in row two of each of Table I and Table II in this amended Form 4. The originally filed Form 4 reported 69,190 options exercised in row two of each of Table 1 and Table II which should have been 69,160, the total amount actually exercised. F3 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 09, 2024 Filed Nov 14, 2024 02:01 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (right to buy) · Derivative | 65,175 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001104659-24-117940 · tm2428383-2_4aseq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,625 Underlying: Common Stock · 65,175 shares Expires 2030-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment is being filed to correct the number of options exercised in row two of each of Table I and Table II in the originally filed Form 4 on February 13, 2024; and to report the exercise of the options in row two of each of Table I and Table II in this amended Form 4. The originally filed Form 4 reported 69,190 options exercised in row two of each of Table 1 and Table II which should have been 69,160, the total amount actually exercised. F2 · derivative.exercise_date: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter. Read SEC document |
| February 09, 2024 Filed Nov 14, 2024 02:01 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,985 | $6.80 | $27,098.00 |
DisclosureSEC source: 0001104659-24-117940 · tm2428383-2_4aseq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment is being filed to correct the number of options exercised in row two of each of Table I and Table II in the originally filed Form 4 on February 13, 2024; and to report the exercise of the options in row two of each of Table I and Table II in this amended Form 4. The originally filed Form 4 reported 69,190 options exercised in row two of each of Table 1 and Table II which should have been 69,160, the total amount actually exercised. Read SEC document |
| February 09, 2024 Filed Nov 14, 2024 02:01 UTC Amendment | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 65,175 | $21.38 | $1,393,441.50 |
DisclosureSEC source: 0001104659-24-117940 · tm2428383-2_4aseq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This amendment is being filed to correct the number of options exercised in row two of each of Table I and Table II in the originally filed Form 4 on February 13, 2024; and to report the exercise of the options in row two of each of Table I and Table II in this amended Form 4. The originally filed Form 4 reported 69,190 options exercised in row two of each of Table 1 and Table II which should have been 69,160, the total amount actually exercised. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:54 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010798 · tm245251-3_4seq1.xml · derivative · entry 3 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,812 Underlying: Common Stock · 3,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:54 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,324 | $45.06 | $59,659.44 |
DisclosureSEC source: 0001104659-24-010798 · tm245251-3_4seq1.xml · nonDerivative · entry 2 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,614 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:54 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-010798 · tm245251-3_4seq1.xml · nonDerivative · entry 1 Shulman Joseph · CIK 0001909855 · Chief Technical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.